Drug Details
General Information of the Drug (ID: DR1957) | ||||
---|---|---|---|---|
Name |
Tapentadol
|
|||
Synonyms |
Nucynta; Palexia; UNII-H8A007M585; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; CG5503; BN 200; CG 5503; Tapentadol (USAN/INN); 3-(1-DIMETHYLAMINO-2-METHYL-PENTAN-3-YL)PHENOL; 175591-23-8
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Acute pain [ICD-11: MG31] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C14H23NO
|
|||
PubChem CID | ||||
Canonical SMILES |
CCC(C1=CC(=CC=C1)O)C(C)CN(C)C
|
|||
InChI |
1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1
|
|||
InChIKey |
KWTWDQCKEHXFFR-SMDDNHRTSA-N
|
|||
CAS Number |
CAS 175591-23-8
|
|||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Epigallocatechin gallate | Hamamelis virginiana | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
EGCG and TAP reduced the proliferation of MDA-MB-231 cells by impairing cell-cycle progression. | |||||
Pregabalin | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | For a xenograft model: Male Sprague Dawley rats (120-140 g) were anaesthetized with isoflurane, and arthritis was induced in the left knee by an intrarticular injection of 2 mg MIA in 25 ul of 0.9% saline. | |||||
Experimental
Result(s) |
The combination therapy of tapentadol and pregabalin restored descending noradrenergic inhibitory tone and also inhibited nociceptive transmission at the level of the spinal cord can provide superior analgesia. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Norepinephrine transporter (NET) | Molecule Info | [1] | |
Opioid receptor mu (MOR) | Molecule Info | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interaction | Click to Show/Hide | ||
2 | Estrogen signaling pathway | |||
3 | Morphine addiction | |||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | Click to Show/Hide | ||
2 | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
3 | Enkephalin release | |||
4 | Adrenaline and noradrenaline biosynthesis | |||
Pathway Interaction Database | IL4-mediated signaling events | Click to Show/Hide | ||
Reactome | Peptide ligand-binding receptors | Click to Show/Hide | ||
2 | G alpha (i) signalling events | |||
3 | Na+/Cl- dependent neurotransmitter transporters | |||
WikiPathways | TCR Signaling Pathway | Click to Show/Hide | ||
2 | GPCRs, Class A Rhodopsin-like | |||
3 | Peptide GPCRs | |||
4 | Opioid Signalling | |||
5 | GPCR ligand binding | |||
6 | GPCR downstream signaling | |||
7 | Monoamine Transport | |||
8 | NRF2 pathway | |||
9 | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds |
